Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression ofcarotid atherosclerosis

Objectives. To study the efficacy of vitamin E and C supplementation on the progression of carotid atherosclerosis, hypothesizing an enhanced preventi ve effect in men and in smokers and synergism between vitamins. Design and subjects. Double-masked two-by-two factorial trial, randomizatio n in four strata (by gender and smoking status) to receive twice daily eith er 91 mg (136 IU) of d-alpha -tocopherol, 250 mg of slow-release vitamin C, a combination of these or placebo for three years. A randomized sample of 520 smoking and nonsmoking men and postmenopausal women aged 45-69 years wi th serum cholesterol greater than or equal to 5.0 mmol L-1 were studied. Setting. The population of the city of Kuopio in Eastern Finland. Intervention. Twice daily either a special formulation of 91 mg of d-alpha -tocopherol, 250 mg of slow-release vitamin C, a combination of these (Cell aVie(R)) or placebo for three years. Measurements. Atherosclerotic progression, defined as the linear regression slope of ultrasonographically assessed common carotid artery mean intima-m edia thickness (IMT), was calculated over semi-annual assessments. Results. The average increase of the mean IMT was 0.020 mm year(-1) amongst men randomized to placebo and 0.018 mm year(-1) in vitamin E, 0.017 mm yea r(-1) in vitamin C and 0.011 mm year(-1) in the vitamin combination group ( P = 0.008 for E + C vs. placebo). The respective means in women were 0.016, 0.015, 0.017 and 0.016 mm year(-1). The proportion of men with progression was reduced by 74% (95% CI 36-89%, P = 0.003) by supplementation with the formulation containing both vitamins, as compared with placebo. Conclusions. Our study shows that a combined supplementation with reasonabl e doses of both vitamin E and slow-release vitamin C can retard the progres sion of common carotid atherosclerosis in men. This may imply benefits with regard to other atherosclerosis-based events.